FDA in­ter­nal re­view points to im­mi­nent Pfiz­er/BioN­Tech EUA, spot­lights po­ten­tial for sin­gle-dose vac­ci­na­tion

Last month
Regulatory
Coronavirus

A KRAS drug is like­ly com­ing — fast — as the FDA points Am­gen’s fron­trun­ner to a loom­ing fin­ish line

Last month
R&D
Regulatory

Glax­o­SmithK­line R&D vet Min Li nabs $100M to launch a Bob Nelsen-backed start­up fo­cused on Chi­na’s bur­geon­ing neu­ro mar­ket

Last month
Financing
Startups

#ASH20 saw a BC­MA brawl. Who's still stand­ing? And who got knocked out for good?

Last month
R&D
Pharma

Carl Hansen is just about ready to grab the key to the ex­clu­sive Cov­il­lion­aire club

Last month
People
Bioregnum

Bay­er picks up off-the-shelf CAR-T ap­proach from Atara, spot­light­ing a Memo­r­i­al Sloan Ket­ter­ing break­through

Last month
Deals
Cell/Gene Tx

#ASH20: Or­ca’s team show­cas­es their first cut of the da­ta on promis­ing cell pu­rifi­ca­tion work for HSCT

Last month
R&D

#ASH20 In a mul­ti­ple myelo­ma show­down, Re­gen­eron march­es out new PhI da­ta for its BC­MA bis­pe­cif­ic

Last month
R&D

#ASH20: As Bris­tol My­ers awaits FDA word, the CAR-T BC­MA lead­ers go head-to-head once again. This time, they're not alone

Last month
R&D
Cell/Gene Tx

#ASH20 Al­lo­gene's David Chang makes the case for an off-the-shelf CAR-T in the jam packed an­ti-BC­MA field

Last month
R&D
Cell/Gene Tx

#ASH20: David Alt­shuler and the Ver­tex/CRISPR team hit a his­toric mile­stone in the hunt for a cu­ra­tive gene edit­ing ap­proach to sick­le cell dis­ease, be­ta tha­lassemia

Last month
Cell/Gene Tx

BioN­Tech chief Ugur Sahin gains star sta­tus in the ex­clu­sive Cov­il­lion­aire club

Last month
People
R&D

Lil­ly part­ners with Unit­ed­Health to con­duct 're­al-world' study for its Covid-19 an­ti­body bam­lanivimab

Last month
Coronavirus

Four biotechs hit Wall Street with up­sized IPOs, each rais­ing more than $20M over their goals

Last month
Financing

Covid-19 roundup: Mod­er­na of­fers glimpse at dura­bil­i­ty da­ta; Bribery scan­dals mar Sino­vac's rep­u­ta­tion

Last month
Coronavirus

A high-pro­file ‘an­gel’ joins the Sil­i­con Val­ley crew back­ing an an­ti-ag­ing up­start with an eye on PhII

Last month
Financing
R&D

Lau­ra Shawver is about to join a line­up of biotech CEOs en­joy­ing overnight for­tunes, cour­tesy of the biotech IPO boom

Last month
People
Financing

This is how Bern­stein divvies up a $40B Covid-19 vac­cine mar­ket among the lead­ers in the race to an ap­proval

Last month
Coronavirus

Covid-19 roundup: In­ovio en­lists plas­mid man­u­fac­tur­er to re­place the one it's in le­gal feud with; Cy­ber­at­tacks spot­ted tar­get­ing vac­cine dis­tri­b­u­tion 

Last month
Coronavirus

Mer­ck sells off its Mod­er­na stake af­ter mak­ing record gains amid the pan­dem­ic

Last month
Pharma

Long af­ter Mer­ck and Bris­tol My­ers cre­at­ed a multi­bil­lion-dol­lar mar­ket, the PD-1 lead­ers are once again duk­ing it out — this time over a $12B-plus pot

Last month
R&D
Pharma

Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing new deals

Last month
Pharma
Cell/Gene Tx

Covid-19 roundup: CDC votes on who should get vac­cines first; As­traZeneca's In­di­an part­ner won't switch dos­ing reg­i­mens

Last month
Coronavirus

For two years, Ovid spun a Phase II miss as a win. The drug just failed Phase III

Last month
R&D
First page Previous page 2345678 Next page Last page